All Immunotherapy articles – Page 4
-
NewsNew enzyme discovery could boost cancer immunotherapy
A new discovery from the University of Geneva highlights the crucial role of the CH25H enzyme, which is found in cancerous lymphatic cells. This enzyme plays a key part in activating immune cells, opening up a promising pathway for improving the success of cancer immunotherapies.
-
NewsThe immune cells that fuel food allergies
A new study reveals how specific immune cells contribute to the exaggerated immune response in food allergies, offering hope for improved treatments in the future.
-
NewsCoherus announces positive Phase II results for liver cancer treatment
Coherus BioSciences shared final data from its Phase II trial of casdozokitug, showing a 17.2 percent complete response rate in liver cancer patients.
-
ReportBeyond the Lab: Stem cell research
Download our latest report to discover how stem cell research is revolutionising treatments for chronic diseases, cancer and regenerative medicine.
-
NewsTessera's gene editing offers hope for sickle cell patients
Find out how Tessera's latest advancements in gene editing bring promising solutions to treat sickle cell disease.
-
ArticleIn vivo CAR T: Faster, cheaper, and more effective cancer care
Find out how in vivo cell therapies could transform cancer treatment by providing faster, more affordable, and accessible options for more patients.
-
ArticleOncology advances through the lens of women in STEM
Dr Pooja Hingorani opens up about her journey in oncology research, the obstacles she’s overcome as a woman in STEM, and her mission to transform cancer care.
-
NewsNKTR-255 shows positive results in lymphoma therapy
Nektar Therapeutics' NKTR-255 improves CAR-T therapy outcomes in lymphoma patients. Find out how this development could impact cancer treatment.
-
ArticleNew targeted therapies show promise in lung cancer treatment
Recent advancements in targeted therapies and immunotherapies are transforming lung cancer treatment. Discover how these innovations are improving outcomes and providing hope for patients.
-
ArticleAI paves the way for new immunotherapy targets
To fully unlock the potential of immunotherapy for cancer patients, we need better targets, not just better treatments. Hear from Michelle Teng, CEO of Etcembly, on how AI is decoding the immune repertoire and designing new therapies.
-
NewsNew DNA nanostructures set to transform cancer treatment
A University of Sydney study reveals how DNA origami can build programmable nanostructures, with promising applications in targeted drug delivery and nanorobotics.
-
NewsNew CAR-T therapy shows promise in leukaemia treatment
Obecabtagene autoleucel (obe-cel) has demonstrated strong efficacy in treating relapsed B-cell leukemia, with high response rates and minimal side effects.
-
NewsBlood-brain barrier breakthrough for ALS and Alzheimer's disease
A new blood-brain barrier-crossing platform enables the delivery of therapeutic molecules to the brain, offering potential treatments for ALS and Alzheimer’s disease.
-
ArticleHarnessing the CD24/Siglec-10 pathway: immunotherapy innovation
Renowned immunologist Dr Yang Liu shares his insights into the preclinical studies behind the development of drug candidates targeting the CD24/Siglec-10 pathway. He discusses the technical and regulatory hurdles of antibody development, how these therapies compare to existing immunotherapies, and the potential for personalised cancer treatment through biomarker development.
-
NewsComputational pipeline for personalised cancer vaccine design
Ludwig Cancer Research researchers have designed and validated a computational pipeline which integrates molecular and genetic analyses.
-
News
New combination treatment enables targeting of non-responsive lung tumours
The newly identified KRAS G12C inhibitor, with SHP2 inhibition, sensitises tumours to immune checkpoint blockade.
-
NewsAnti-PD-1 autoantibody: a biomarker candidate for HCC
The researchers discovered that anti-PD-1 autoantibodies influence the outcome of Atezo/Bev therapy for hepatocellular carcinoma.
-
NewsMelanoma: predicting immunotherapy-induced side effects
Increased gene activity in the SYK pathway could be the basis of a blood test to identify melanoma patients most susceptible to severe side effects.
-
NewsType 1 regulatory cells limit immunotherapy success
Scientists discovered the number of Tr1 cells increased as tumours grew larger, making mice insensitive to immunotherapy.
-
NewsProstate cancer: delaying resistance to hormone therapy
Researchers have developed a new form of immunotherapy that could provide a longer life expectancy to men with prostate cancer.